CClinicalTrials.gg
Not yet recruitingNCT07572266BOOST-XUpdated Aug 10, 2026

Adjuvant Nitrate to Boost Exercise-induced Health Benefits in Older Adults

An interventional study of Nitrate enriched beetroot juice and Nitrate depleted beetroot juice in Aging, Aging Well and Healthy Aging, sponsored by Florida Institute for Human and Machine Cognition. Not yet recruiting at 1 site in United States. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Florida Institute for Human and Machine Cognition · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
226
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

Aging-related functional declines are thought to be caused by hallmark biological processes that ultimately manifest in physical, mental, and metabolic impairments to compromise intrinsic capacity and healthspan. Exercise is the only multipotent treatment with promise to mitigate many of the aging hallmarks, but there is substantial variability in individual exercise responsiveness. Thus, the investigators approach to boosting exercise responsiveness in aging is to combine an exercise training prescription containing both endurance and resistance training (in alignment with DHHS guidelines) with a nitrate-enriched dietary supplement to augment the cellular, tissue, and systemic adaptations that induce myriad health benefits of exercise in older adults.

Read the detailed description

Aging-related declines in health and intrinsic capacity are linked to biological processes profoundly affecting all organ systems and tissues including skeletal muscle. Exercise is a multipotent countermeasure to these processes. However, there is significant inter-individual response heterogeneity (IRH) in the magnitude of exercise-induced health benefits. Boosting exercise responsiveness among older adults is thus a top priority. The investigators have found in older adults that supplementation with nitric oxide (NO) precursors nitrate and nitrite is safe, well tolerated, and improves: (i) physical performance; (ii) vascular endothelial function; (iii) mitochondrial function; (iv) oxidative stress; and (v) muscle inflammation. The investigators suspect deficits among some older adults in nitrate bioavailability and/or exercise-induced NO production may in part drive suboptimal exercise responsiveness. Given the powerful and sustaining impact of exercise-induced health benefits on morbidity and mortality, the investigator's fundamental premise is that exercise responsiveness of every older adult should be maximized. In the BOOST-X Trial the investigators will determine if increasing nitrate bioavailability via dietary supplementation is an efficacious approach to more older adults attaining these essential health benefits. Low cardiorespiratory fitness (CRF, VO2max) and low functional muscle quality (fMQ; strength/muscle mass) are multi-system manifestations of degenerative aging that include vascular endothelial and mitochondrial dysfunction, oxidative stress, and inflammation. CRF and fMQ are modifiable with endurance (ET) and resistance (RT) training. This planned trial will be the first to evaluate the efficacy of coupling a nitrate-rich nutritional supplement with a combined ET+RT prescription in line with DHHS weekly exercise guidelines. The investigators will test the central hypothesis that daily nitrate supplementation will augment exercise training-induced gains in CRF and fMQ accompanied by improvements in vascular endothelial and mitochondrial function. Aim 1: Assess the clinical impact of nitrate supplementation on the proportion of older adults attaining exercise-induced health benefits. N=226 participants stratified by sex and age group (60-69 vs ≥70 y) with random assignment to nitrate (400 mg, 2x/day) (n=113) vs. placebo (nitratedepleted) (n=113) during 12 wk of 3x/wk ET+RT. 1˚ Outcomes: MCID attainment for CRF and fMQ. Expected Results: Daily nitrate will reduce the proportion of older adults not attaining CRF and fMQ MCIDs by a full 1/3. Aim 2: Assess potential mechanisms underpinning adaptations to exercise +/- nitrate supplementation. The investigators will test/integrate in vivo, ex vivo, in vitro and molecular mapping assays considered central to exercise +/- nitrate adaptations and leverage a multidimensional learning framework to better understand the biocircuitry underpinning MCID attainment. 1˚ Outcomes: Vascular endothelial function, muscle mitochondrial function. Expected Results: MCID attainment will be closely linked to improvements in vascular endothelial function and muscle mitochondrial function. The acute molecular responses to exercise will be differentially regulated by nitrate supplementation, and the novel biocircuitry will reveal key features that influence adaptability.

02

Conditions studied

  • Aging
  • Aging Well
  • Healthy Aging
03

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Male or female aged 60 years or older
  2. Free of chronic disease or disorder that would preclude full participation or have the potential to confound results
  3. No structured exercise program (2 or more bouts/wk) within previous 12 months
  4. Cognitively capable of providing informed consent

Exclusion criteria

Exclusion Criteria:

  1. BMI ≥ 30.0 kg/m2
  2. Neurodegenerative disease
  3. Neuromuscular, musculoskeletal or orthopedic disorder or condition that would limit ability to perform the exercise prescription and/or physical performance testing
  4. Diagnosed orthostatic hypotension, i.e., a drop in systolic blood pressure of at least 20 mmHg or a drop in diastolic blood pressure of at least 10 mmHg within three minutes of standing up from a sitting or lying position.
  5. Resting blood pressure \<90/60 mmHg or >160/95 mmHg
  6. Uncontrolled hypertension
  7. Any current cardiovascular disease or cardiopulmonary instability
  8. Recent cardiovascular event or procedure within the preceding 6 months

    1. If valve replacement has been performed, patient may not be enrolled for 12 months after the procedure
    2. Any mechanical valve replacement that requires continuous warfarin anti-coagulation
  9. Anemia: Hgb \<11.0 (♂),10.0 (♂) gm/dl
  10. Diabetes with HgbA1c >7.0% or fasting blood glucose ≥ 130 mg/dl
  11. Liver disease with ALT > 52 U/l)
  12. Chronic kidney disease (eGFR \< 45)
  13. Any current infectious disease
  14. Any other disease or disorder that could influence exercise response, preclude full participation or have the potential to confound results (e.g., chronic lung disease, cognitive impairment, current cancer diagnosis or within 2 yr remission, cerebrovascular disease, pain)
  15. Life expectancy \< 1 year Medications / lifestyle
  16. Insulin sensitizing/blood glucose lowering agents such as metformin
  17. Currently on or have used GLP-1 agonist or other metabolic / weight loss drug in previous 12 weeks
  18. Use of nitrate medications
  19. High dose statin (≥40 mg/d simvastatin equivalence)
  20. Chronic corticosteroids
  21. Testosterone or other anabolic/androgenic hormone therapy
  22. Lidocaine allergy
  23. Regular tobacco use and/or vaping > 1/wk
  24. Use of cannabis > 1/wk
  25. Excessive alcohol consumption (3 drinks/d or 7 drinks/wk for females; 4 drinks/d or 14 drinks/wk for males)
  26. Use of illicit drugs (e.g., cocaine, opioids)
  27. Unable to commit to \~4 months required to complete the study
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
226 participants (estimated)

Study arms

  • Experimental
    Nitrate Group

    Participants will be randomized to an intervention in which they take 800 mg (2 x 400 mg) nitrate-enriched beetroot juice drink \[Beet It Sport Nitrate 400 (70 ml per drink)\]. Both nitrate and placebo will be purchased from Beet It.

    Dietary Supplement: Nitrate enriched beetroot juice · Other: 12 week of combined exercise training

  • Placebo comparator
    Placebo Group

    Participants will be randomized to an intervention in which they take 800 mg (2 x 400 mg) nitrate-deprived, manufacturer-matched beetroot juice drink \[Beet It Sport Nitrate 400 (70 ml per drink)\]. Both nitrate and placebo will be purchased from Beet It.

    Dietary Supplement: Nitrate depleted beetroot juice · Other: 12 week of combined exercise training

Interventions

  • Dietary supplementNitrate enriched beetroot juice

    Participants will be randomized to an intervention in which they take 800 mg (2 x 400 mg) nitrate-enriched beetroot juice drink \[Beet It Sport Nitrate 400 (70 ml per drink)\]. Both nitrate and placebo will be purchased from Beet It.

  • Dietary supplementNitrate depleted beetroot juice

    Manufacturer-matched placebo that is nitrate-depleted beetroot juice (70 ml per drink). Both nitrate and placebo will be purchased from Beet It.

  • Other12 week of combined exercise training

    All participants: An exercise dose will be composed of 12 wk of 3d/wk laboratory based supervised prescribed with strategic variations in intensity, volume, and modality across the 3 weekly sessions. During Monday and Friday RT sessions, participants complete 3 sets x 8-12 reps to volitional fatigue for leg press, knee extension, leg curl, overhead press, lat pulldown or row, and chest press in superset fashion with a 60 s rest between supersets. On Wednesday, participants perform 2 sets of 13-15 reps of leg press, knee extension, chest press and lat pulldowns with specific cues for speed and fast contractions. RT is complemented by the ET component which follows a Moderate-High Moderate intensity schedule with 30 min of 70-75% HRR steady state cycling on Monday and Friday separated by a Wednesday 20 min high intensity interval session on a cycle ergometer (1 min on/off; 10 cycles) at near maximal intensity with a target of 90% HRR.

05

What researchers measure

Primary outcomes

  1. Assess the clinical impact of nitrate supplementation on a proportion of older adults attaining exercise-induced health benefits.

    The primary outcome will be assessed using logistic regression with the proportion not attaining Cardiorespiratory Fitness and functional Muscle Quality Minimally Clinical Differences as the response variable and treatment adjusted for sex and age group across the 12 week intervention.

    Time frame: 12 weeks

Secondary outcomes

  1. Cardiorespiratory demand during submaximal cycle exercise.

    Supportive analyses will include secondary (cardiorespiratory demand during submaximal steady state exercise) outcomes. The steady state exercise cycling will be 10 minutes at 60% of peak power (Watts) during the VO2 peak test.

    Time frame: 12 weeks

  2. Neuromuscular fatiguability during isometric holds.

    The knee extensors will perform a 30 second isometric flexion on a dynamometer. The fatigue will be defined by the force decline across the 30 seconds.

    Time frame: 12 weeks

  3. 10 meter max gait speed.

    Participants will walk as quickly as possible across a 10 meter, straight course. Time is recorded for up to three attempts. A lower time indicates a faster speed.

    Time frame: 12 weeks

  4. modified Balance Error Scoring System (mBESS)

    Stability is assessed with the Sway Medical tablet app via three stances: double-leg, single-leg, and tandem. Scoring is decided by losing balance or opening eyes during closed eyed tests.

    Time frame: 12 weeks

  5. NIH PROMIS Physical Function SF

    The NIH PROMIS Physical Function Short Form (SF) is a standardized tool used to evaluate an individual's physical abilities and limitations in daily activities. It is part of the broader Patient-Reported Outcomes Measurement Information System (PROMIS), which focuses on measuring patient-reported outcomes across various health domains.

    Time frame: 12 weeks

  6. NIH PROMIS Fatigue SF

    PROMIS Fatigue SF refers to the short form of the Patient-Reported Outcomes Measurement Information System designed to assess fatigue levels in patients. It provides a standardized way to measure fatigue, which can be used in various clinical settings to evaluate patient health status.

    Time frame: 12 weeks

Other outcomes

  1. Cognitive function.

    Cognitive function is assessed via Sway Medical reaction time via three assessments: visual processing speed: measures how quickly a person can interpret visual information.

    Time frame: 12 weeks

  2. Psychological state.

    Depression and anxiety are assessed via the well-validated Patient Health Questionnaire 9 (PHQ-9) both via Sway. The PHQ-9, or Patient Health Questionnaire-9, is a tool used to screen for, diagnose, and measure the severity of depression. It consists of nine questions that assess how often a person has experienced symptoms of depression over the past two weeks.

    Time frame: 12 weeks

  3. Sleep quality and nocturnal stress.

    Perceptions of sleep quality are measured using the short forms (SF) of PROMIS Sleep Disturbance and Sleep-Related Impairment. For direct monitoring, participants wear an Oura Gen-4 ring to quantify sleep behavior with stress monitored via Heart Rate /Heart Rate variability (HRV) across the full enrollment period, as we have done in previous studies including the ongoing NIA M3AX Trial (NCT06507189). The Oura ring is well validated against polysomnography for several sleep metrics and nocturnal HR/HRV.

    Time frame: 12 weeks

  4. Free-living activity via the Oura Gen 4.

    Free-living activity is also monitored daily via the Oura Gen-4 ring worn throughout trial participation. Variables such as step count and heart rate will used to determine activity.

    Time frame: 12 weeks

06

Study locations

1 site
  • Florida Institute for Human and Machine Cognition
    Pensacola, Florida 32502, United States
07

References and documents

Individual participant data

Plan to share: Yes — De-identified phenotyping data will be made accessible through supplementary data tables and files alongside manuscript publication or via third-party repositories. This data will also be hosted on secure server space without any link to PHI and made accessible through a publicly available Shiny app. Primary cell aliquots and biobanked snap frozen muscle and/or frozen blood samples will be provided to investigators upon reasonable request along with de-identified metadata.

Supporting information: Study protocol, Sap, Icf, Csr

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07572266
Lead sponsor
Florida Institute for Human and Machine Cognition
Responsible party
Sponsor
First posted
May 7, 2026
Start date
Nov 2026 (estimated)
Primary completion
May 2031 (estimated)
Completion
May 2031 (estimated)
Last update
Aug 10, 2026

Study contacts

Craig Tuggle, MA
Contact
ctuggle@ihmc.org
850-202-4416

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion